Usefulness of simple assays for serum concentration of hepatitis C virus RNA and HCV genotype in predicting the response of patients with chronic hepatitis C to interferon α2a therapy

Journal of Medical Virology

Volumn 46, Issue 2, 1995, Pages 162-168

  Suzuki, Toshio ^a   Tanaka, Eiji ^a   Matsumoto, Akihiro ^a   Urushihara, Akihiko ^a   Sodeyama, Takeshi ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

branched DNA assay; genotyping enzyme linked immunosorbent assay; hepatitis C virus; interferon

Indexed keywords

ALPHA2A INTERFERON; VIRUS RNA;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION;

ADULT; AGED; ALANINE TRANSAMINASE; CHRONIC DISEASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON ALFA-2A; INTERFERON TYPE I, RECOMBINANT; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; REAGENT KITS, DIAGNOSTIC; RNA, VIRAL; TREATMENT OUTCOME;

HEPATITIS C VIRUS;

EID: 0029061728     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.1890460215     Document Type: Article

References (29)

1. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non‐A, non‐B hepatitis
2. Genotypic subtyping of hepatitis C virus
3. Treatment of chronic hepatitis C with recombinant interferon alfa
4. Re‐combinant interferon alfa therapy for chronic hepatitis C
5. Treatment of chronic hepatitis C with recombinant human interferon‐a2a: Results of a randomized controlled clinical trial
6. Randomized controlled trial of recombinant alpha‐2a‐interferon for chronic hepatitis C, comparison of alanine aminotransferase normalization versus loss of HCV RNA and anti‐HCV IgM
7. There are two types of hepatitis C virus in Japan
8. Genotypes and titers of hepatitis C virus for predicting response to interferon in patients with chronic hepatitis C
9. Treatment of chronic hepatitis C with high‐dose interferon a‐2b: A multicenter study
10. Neutralization of interferon by antibody: Appraisals of methods of determining and expressing the neutralization titer
11. Interrelationship of blood transfusion, non‐A, non‐B hepatitis and hepatocellular carcinoma: Analysis by detection of antibody to hepatitis C virus
12. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis
13. Avoiding false positives with PCR
14. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C
15. Hepatitis C virema in chronic liver disease: Relationship to interferon‐a or corticosteroid treatment
16. Viral and host factors that contribute to the efficacy of interferon alpha 2a therapy in patterns with chronic hepatitis C
17. Neutralizing antibodies to recombinant alpha‐interferon and response to therapy in chronic hepatitis C virus infection
18. Detection of hepatitis C virus RNA by a two‐stage polymerase chain reaction with two pairs of primers deduced from the 5′‐noncoding region
19. The 5′‐terminal sequence of the hepatitis C virus genome
20. Typing hepatitis C virus by polymerase chain reaction with type specific primers: Application to clinical surveys and tracing infectious sources
21. Hepatitis C virus infection associated with the development of hepatocellular carcinoma
22. Sequence variability in the 5′ non coding region of hepatitis C virus: Identification of a new virus type and restrictions on sequence diversity
23. A proposed system for the nomenclature of hepatitis C viral genotypes
24. Clinical significance of antibodies to nonstructural and core proteins of hepatitis C virus in posttransfusion hepatitis patients during long‐term follow‐up
25. Prevalence of hepatitis C virus with different genotypes determined by a group specific antibody assay in Japanese patients with chronic liver diseases due to hepatitis C virus infection
26. Significance of specific antibody assay for genotyping of hepatitis C virus
27. Factors predictive of response to Interferon‐ α therapy in hepatitis C virus infection
28. Antigenenicitis of group l and 2 hepatitis C virus polypeptides‐molecular basis of diagnosis
29. Detection of hepatitis C virus by polymerase chain reaction and response to interferon‐a therapy